L01FMonoclonal Antibodies And Antibody Drug Conjugates
Subgroups
- CD20 (Clusters of Differentiation 20) inhibitorsL01FA
- CD22 (Clusters of Differentiation 22) inhibitorsL01FB
- CD38 (Clusters of Differentiation 38) inhibitorsL01FC
- HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsL01FD
- EGFR (Epidermal Growth Factor Receptor) inhibitorsL01FE
- PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsL01FF
- VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsL01FG
- Other monoclonal antibodies and antibody drug conjugatesL01FX
- Combinations of monoclonal antibodies and antibody drug conjugatesL01FY
Substances
- bevacizumabL01FG01
- trastuzumabL01FD01
- rituximabL01FA01
- pertuzumabL01FD02
- nivolumabL01FF01
- pembrolizumabL01FF02
- daratumumabL01FC01
- cetuximabL01FE01
- amivantamabL01FX18
- atezolizumabL01FF05
- isatuximabL01FC02
- ado-trastuzumab emtansineL01FD03
- durvalumabL01FF03
- elotuzumabL01FX08
- gemtuzumab ozogamicinL01FX02
- ipilimumabL01FX04
- mosunetuzumabL01FX25
- obinutuzumabL01FA03
- ofatumumabL01FA02
- panitumumabL01FE02
- tislelizumabL01FF09
- blinatumomabL01FX07
- brentuximab vedotinL01FX05
- enfortumab vedotinL01FX13
- inotuzumab ozogamicinL01FB01
- tafasitamabL01FX12
- tremelimumabL01FX20
- belantamab mafodotinL01FX15
- epcoritamabL01FX27
- glofitamabL01FX28
- ramucirumabL01FG02
- retifanlimabL01FF10
- talquetamabL01FX29
- teclistamabL01FX24
- trastuzumab deruxtecanL01FD04
- zolbetuximabL01FX31
- avelumabL01FF04
- dostarlimabL01FF07
- linvoseltamabL01FX37
- loncastuximab tesirineL01FX22
- mirvetuximab soravtansineL01FX26
- mogamulizumabL01FX09
- sacituzumab govitecanL01FX17
- tisotumab vedotinL01FX23
- toripalimabL01FF13
- moxetumomab pasudotoxL01FB02
- naxitamabL01FX21
- necitumumabL01FE03
- olaratumabL01FX10
- tarlatamabL01FX33